SYGNIS AG announced the completion of the relocation of its subsidiary company, Innova Biosciences, into the Company’s existing facilities in Cambridge, UK.
Move forms part of integration into SYGNIS Group
Madrid, Spain and Heidelberg, Germany, 18 October 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the relocation of its subsidiary company, Innova Biosciences, into the Company’s existing facilities in Cambridge, UK.
The relocation follows the recent acquisition of Innova Biosciences by SYGNIS AG, and the continued integration of Innova within the SYGNIS Group of companies. This change completes the relocation of Innova’s R&D, manufacturing and logistics departments. To enable the relocation, the Company has invested in the development of 3,000 sqft of new laboratory space at its Cambridge facility. This has doubled the Group’s R&D capabilities in Cambridge and also provides the necessary space and resource required to meet the increasing demand for the Company’s services offering, as well as allow for expansion of its kit manufacturing capabilities.
The R&D facility at Cambridge will predominantly focus on proteomics product and technology development whilst genomics R&D will continue to be based at the Group’s facility in Madrid, Spain. Whilst the R&D effort is located in core centres of excellence in different geographic locations, the groups are interacting closely together on the Group’s core projects in the fields of liquid biopsy and lateral flow assay technology in development with several new joint projects feeding into product development pipeline.
Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, commented: “We have seen rapid growth in demand for the innovative products and services across the entire spectrum of the Company’s offering ranging across the fields of genomics, proteomics and immunology. Amongst the drivers of this demand are Innova`s easy-to-use, cutting-edge bioconjugation technologies and services. With the combination of our sites in Cambridge, the acquisition and relocation of Innova into the SYGNIS Group has been completed. The relocation and site expansion sets the Group up well to continue along its strong growth path to continue to delivering new innovative and high added value products and services for our customers.”
ENDS
For further information, please contact:
SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
MC Services AG (Financial Media and Investor Relations)
Dr. Claudia Gutjahr-Loeser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG develops and commercialises value-added, easy-to-use, reliable products based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With the acquisitions of Expedeon Holdings, Ltd. in 2016 and both C.B.S. Scientific Company, Inc. and Innova Biosciences Ltd. in 2017, SYGNIS significantly expanded its product line and now covers the entire molecular biology workflow, including genomics, proteomics and tools as well as cutting-edge bioconjugation technologies and services. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. The SYGNIS Group has offices in Germany, Spain and the UK; production sites in the UK and the U.S. and sales offices in Asia. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).
About Innova Biosciences
Innova Biosciences (Innova) is a member of the SYGNIS group of companies, which also includes Expedeon and CBS Scientific, with a product portfolio covering the entire workflow of molecular biology.
Innova is a world leading expert in easy-to-use, cutting-edge high quality bioconjugation technologies, products and services, supporting scientists from academia through to commercial manufacturing. Products and services are based on its antibody and protein labeling, oligonucleotide labeling, particle and phosphate detection enzyme assay technologies, and include the Lightning-Link®, InnovaCoat® and Thunder-Link® brands.
